Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 1, 2021

University of Kent research identifies novel Covid-19 therapy

According to findings, Benfooxythiamine can hinder the replication of the SARS-CoV-2 virus with infected cells that did not produce new viruses.

Scientists at the School of Biosciences of the University of Kent and the Institute of Medical Virology at Goethe-University, Frankfurt am Main, have identified a novel therapy, benfooxythiamine, which hinders the SARS-CoV-2 replication.

All viruses, including coronaviruses, multiply by entering the cells and reprogramming them to make new viruses.

The Covid-19 infected cells can create new coronaviruses only by activating their metabolic pentose phosphate pathway, the findings showed.

An inhibitor of this pathway, benfooxythiamine was found to hinder SARS-CoV-2 replication with infected cells that did not create new viruses.

Furthermore, the scientists found that the therapy boosted the antiviral activity of the ‘2-deoxy-D-glucose’ drug that alters the metabolism of the host cell to inhibit the growth of the virus.

This suggests that inhibitors of the pentose phosphate pathway, such as benfooxythiamine, could become a promising therapy option to treat Covid-19, as monotherapy and in conjunction with other medicines.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Kent School of Biosciences professor Martin Michaelis said: “This is a breakthrough in the research of Covid-19 treatment.

“Since resistance development is a big problem in the treatment of viral diseases, having therapies that use different targets is very important and provides further hope for developing the most effective treatments for Covid-19.”

The antiviral mechanism of benfooxythiamin varies from remdesivir and molnupiravir, other Covid-19 treatments. As a result, viruses that are resistant to these therapeutics could be sensitive to benfooxythiamin.

Goethe-University Frankfurt professor Jindrich Cinatl said: “Targeting virus-induced changes in the host cell metabolism is an attractive way to interfere specifically with the virus replication process.”

In March, researchers from the University of California, Los Angeles and universities in California, Delaware and Germany and Merck identified a compound, berzosertib, which demonstrated potential in treating Covid-19.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU